Elevance Health, Inc. (ELV) experienced a tumultuous run, marked by episodes of drastic losses, significant gains, and a topsy-turvy path on the stock market. The healthcare stock tardily oscillated with reports pointing to the cutting of profit forecast due to
high medical costs, yet it eventually presided over a remarkable
fourth quarter and full-year 2024 results. The year 2025 promises a bright outlook for ELV, spurred on by a 3.1% jump indicative of potential strength. Despite a significant
Medicaid member drop in Q4, ELV posted a resounding revenue of $45B. Its Q4 sales reported an alignment with estimates while also boosting its dividend to $1.71. Monitoring the trends in ELV's performance, it is unequivocal that investing in ELV five years back would have led to impressive gains. However, velvet-lined circumstances aside, there were notable slips; ELV faced a severe slide with the stock losing 24% in the last year and experiencing a nerve-wracking 29.6% plunge in Q4. ELV's incursion into Medicare expansion through acquisitions and its sessions of beating revenue estimates and expected earnings growth, however, paints a picture of a juggernaut bracing itself for stronger performance.
Elevance Health ELV News Analytics from Wed, 31 Jul 2024 07:00:00 GMT to Wed, 19 Mar 2025 16:45:20 GMT -
Rating 5
- Innovation 3
- Information 7
- Rumor 2
